Meet with our product experts in one-on-one virtual sessions
Set Up a Meeting
Transforming for a sustainable future
Providing cures and reducing the disease burden are central to our purpose as a leading pharma company. We have always held a holistic worldview that regards society and the environment as being interdependent, helping to assure human health and well-being, a sustainable planet, and a well-integrated society.
In 2022, building on our incremental work in sustainability, and close on the heels of a waning pandemic that had devastated mankind, Dr. Reddy’s launched its sustainability vision for 2030. Spanning across diverse areas we care about—from environmental and social sustainability to stronger governance, from greater access and affordability of medicines to public health issues, from greater economic equity and accountability to acceptance of greater social parity—our sustainability goals reveal our bold vision for the future and what we collectively strive to achieve every day.
Our purpose “Good health can’t wait” translates into three pillars with sustainability at the core
Our sustainability/ESG goals
We believe that our strength in innovation, ethical values and focus on bringing critical, life-saving products early to market secures a unique kind of sustainability for us. Our leadership across global markets is indicative of our strong alignment with our ‘Good Health Can’t Wait’ agenda.
While we renewed our goals in 2020 to adapt to changing stakeholder expectations, address climate change, and our resolve to work on material issues, we continued to examine more ways to make an impact. We consulted a larger set of global sustainability and pharmaceutical standards and frameworks, and these findings guided our ESG reviews with the leadership and Board.
Combining a top-down and bottom-up approach, using more tools such as our updated enterprise risk management findings, we set 14 bold and ambitious goals across the ESG dimensions to form our vision for 2030. Each of these goals takes into consideration our critical material topics, the external environment in which we operate, and the business and social impact that we can create.
Our new sustainability goals
Being committed to environmental stewardship
- Reducing carbon emissions
- Water positivity
Making our products accessible and affordable for patients
- Access
- Affordability
- Innovation
Contributing to a fairer and more socially inclusive world
- Equity, diversity, and inclusion
Enhancing trust with our stakeholders
- Highest standards of compliance
- ESG disclosures
- Strategic suppliers
Highlights of 2022
Increasing reach, easing access, creating greater cross-sectional impact
Supporting communities with targeted social and environmental actions
Consistently strengthening governance standards
Creating a resilient and responsible supply chain
Building a skilled and empowered workforce with greater social equity
Our emissions reduction journey towards decarbonisation
| Grade/Score | Level | Recognized by |
|---|---|---|
| B | Management level score | CDP climate change 2021 |
| A- | Leadership level score | CDP water security 2021 |
| A | Top 8% of companies assessed by CDP | CDP supplier engagement leader board 2021 |
| 75/100 | 9th of 331 global pharma companies | Dow Jones Sustainability Indices 2021 |
| 47/100 | Good performance rating | Eco Vadis 2022 |
Active Pharmaceuticals Ingredients (APIs)
In our core API business, our focus on innovation-led affordability gives our customers access to the most complex active ingredients, while maintaining a consistent global quality standard. Our partnerships with leading generic formulation brands to fulfil their drug development needs has also given an edge to our own generics business, enabling us to deliver higher quality at competitive costs.
We are present across multiple channels, with customer engagements along different points in the development and manufacturing value chain—from discovery and CDMO (Contract Development & Manufacturing Organisation) services to development, manufacture, and sales. Through integrated discovery and CDMO services, we have executed more than 500 projects over 20 years.
Highlights for the year
Our Sustainability Framework
At Dr. Reddy's, we are committed to taking meaningful action for a sustainable future. With our long-standing commitment to protecting the environment, we are working on solutions that help minimize the impact of our operations, driving improvements in multiple areas at various stages of the product life cycle.
Looking at issues of maximum importance to our stakeholders and the business, we are in the process of identifying material issues and building our strategic sustainability framework. We will develop ambitious goals and management targets for each focus area, with multiple milestones, incorporating governance systems and
processes, monitoring, and disclosing our performance for each goal, and ensuring independent third-party assurance.
We are determined to play our part in upholding the more prominent global perspective. We will align ourselves with the United Nations' sustainable development goals (UN SDGs), mapping them with our top material issues, allocating internal resources, taking relevant actions, and building technical capabilities. We are also working on greater integration of ESG into our business and building stronger stakeholder relationships by intensifying dialogue and communicating our vision and progress around material issues.
The ESG principles underlie our business strategy. We address customer needs and create value for all stakeholders by addressing unmet needs. We are conscious of our footprint and impact and believe that addressing sustainability challenges is the need of the hour. Therefore, we continue to follow the best practices to make our business more sustainable.
R&D Operations Guided by Sustainability Framework
Since 2010, Dr. Reddy's has been committed to the UN Global compact corporate responsibility initiative and its principles in the environment, sustainability, and green chemistry. As an active pharmaceutical ingredient supplier, our primary goal is to develop products that will provide a reliable supply of products of superior quality for the pharmaceutical industry. Also, we ensure that our APIs are produced using eco-friendly processes so that our customers can sustainably access our APIs.
Robust Supply chain
Our supply chain process is based on a strategic model to ensure a practical, reliable, and sustainable supply of goods and services based on a segmented operation. A scorecard is generated for all the KPIs, and we monitor the progress toward each goal. In addition, a well-defined Supplier Code of Conduct (SCOC) governs our supply chain management. We also have a dedicated SCM (Supply Chain Management) team that addresses all sustainable sourcing elements with special emphasis on supply continuity, quality and compliance, supplier relationships, capacity and capability building, supplier, and performance management, and aligning the partners with our vision of sustainability. regulatory documents).
Strong partner network - Intelligence to get early alerts on issues, enabling us to take corrective actions.
collaboration groups - Support groups of transporters, shippers, airlines, etc., came together for information sharing and solutions
Opening ourselves to new possibilities - Adopting new solutions such as moving cold chain products by road and sea, expanding our logistics footprint to new ports and airports, introducing new origin and destination pairs, and exploring digital technology (e.g., digital signatures for regulatory documents).
Renuncia
Ninguna información en este catálogo, incluida cualquier referencia a cualquier producto o servicio, constituye una oferta de venta, ni debe interpretarse como representación de una oferta de venta. Los productos protegidos por patentes válidas no se ofrecen ni se suministran para uso comercial. Sin embargo, las cantidades de investigación de dichos productos pueden ofrecerse con el fin de presentaciones reglamentarias, siempre que existan dichas exenciones reglamentarias. Los compradores deben realizar una evaluación independiente del escenario de la patente para sus respectivos mercados y serán responsables de todas las responsabilidades relacionadas con la patente. Los productos protegidos por patentes válidas en la India no están disponibles para uso comercial, pero estarían disponibles para los fines de la Sección 107A.